Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients with Coronavirus Disease 2019 and Primary Antibody Deficiency

9Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019. Methods: We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects. Results: Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days. Conclusions: The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.

Cite

CITATION STYLE

APA

Pulvirenti, F., Milito, C., Cinetto, F., Fernandez Salinas, A., Terreri, S., Piano Mortari, E., … Quinti, I. (2022). Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients with Coronavirus Disease 2019 and Primary Antibody Deficiency. Journal of Infectious Diseases, 225(5), 820–824. https://doi.org/10.1093/infdis/jiab554

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free